SB290157 (trifluoroacetate)
SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
Product Specifications
CAS Number
[1140525-25-2]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Complement System
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/SB290157_trifluoroacetate.html
Concentration
10mM
Purity
99.87
Solubility
DMSO : 100 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)
Smiles
N=C(N)NCCC[C@@H](C(O)=O)NC(COCC(C1=CC=CC=C1)C2=CC=CC=C2)=O.OC(C(F)(F)F)=O
Molecular Formula
C24H29F3N4O6
Molecular Weight
526.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Ames RS, et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3areceptor that demonstrates antiinflammatory activity in animal models. J Immunol. 2001 May 15;166 (10) :6341-8.|[2]Hutamekalin P, et al. Effect of the C3a-receptor antagonist SB 290157 on anti-OVA polyclonalantibody-induced arthritis. J Pharmacol Sci. 2010;112 (1) :56-63.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Aging Cell. 2025 Jun 20:e70145.|Animals (Basel) . 2023 Feb 24;13 (5) :837.|Biochem Pharmacol. 2025 Oct 13:117421.|bioRxiv. 2025 January 17.|bioRxiv. 2025 May 29:2025.05.26.656101.|Brain Behav Immun. 2024 Sep 15:S0889-1591 (24) 00625-1.|Brain Sci. 2023 Feb 3;13 (2) :262.|Cell Death Dis. 2021 Mar 26;12 (4) :327.|Free Radic Biol Med. 2023 Feb 1:195:329-342.|Front Cell Dev Biol. 2021 Jun 2:9:686886.|Gut Microbes. 2025 Dec;17 (1) :2484386.|Immunobiology. 2023 Jan 18;228 (2) :152337.|Inflammation. 2024 Nov 11.|Int Dent J. 2025 Mar 25;75 (3) :1649-1661.|Int Immunopharmacol. 2020 Oct;87:106814.|Int J Mol Med. 2025 Dec;56 (6) :223.|J Am Soc Nephrol. 2022 Sep;33 (9) :1742-1756.|J Neuroinflammation. 2021 Feb 15;18 (1) :43.|J Neuroinflammation. 2024 Sep 16;21 (1) :227.|J Transl Med. 2023 Dec 11;21 (1) :904.|JCI Insight. 2025 Feb 13;10 (6) :e184141.|Mater Sci Eng C Mater Biol Appl. 2021 Mar:122:111932.|Mol Neurobiol. 2024 Dec;61 (12) :10246-10270.|Neurobiol Dis. 2025 Sep 22:216:107117.|Neurosci Lett. 2023 Feb 6:796:137049.|Prog Neurobiol. 2024 Jun 28:102654.|Research Square Preprint. 2020 Sep.|Toxicol Lett. 2023 May 15:381:27-35.|Cell Death Dis. 2020 May 15;11 (5) :377.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1067672-01 0.02 mg (E-Coli)
Recombinant Escherichia coli Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details 
MBS1067672-02 0.1 mg (E-Coli)
Recombinant Escherichia coli Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details 
MBS1067672-03 0.02 mg (Yeast)
Recombinant Escherichia coli Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details MBS1067672-04 0.1 mg (Yeast)
Recombinant Escherichia coli Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details MBS1067672-05 0.02 mg (Baculovirus)
Recombinant Escherichia coli Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details MBS1067672-06 0.02 mg (Mammalian-Cell)
Recombinant Escherichia coli Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details